Brief: Gentian Diagnostics Q4 EBITDA Loss NOK 1.5 Mln
16/02/2023 07:18
Feb 16 (Reuters) - Gentian Diagnostics ASA GENT.OL :
* SALES OF MNOK 27.9 IN Q4 22, UP 28% (23% ORGANIC GROWTH)
FROM
4Q21
* EBITDA WAS MNOK -1.5 IN 4Q22
Source text for Eikon: ID:nObiLdkK4a
Further company coverage: GENT.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Gentian Diagnostics ASA
See all newsBrief: Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
Brief: Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
Brief: Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
Brief: Gentian Diagnostics Q4 EBITDA NOK 10.5 Million
Brief: Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company